Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis
Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injec...
Gespeichert in:
| Veröffentlicht in: | Pain (Amsterdam) 2004-09, Vol.111 (1), p.169-180 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 180 |
|---|---|
| container_issue | 1 |
| container_start_page | 169 |
| container_title | Pain (Amsterdam) |
| container_volume | 111 |
| creator | Sevcik, Molly A. Luger, Nancy M. Mach, David B. Sabino, Mary Ann C. Peters, Christopher M. Ghilardi, Joseph R. Schwei, Matthew J. Röhrich, Heidi De Felipe, Carmen Kuskowski, Michael A. Mantyh, Patrick W. |
| description | Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival. |
| doi_str_mv | 10.1016/j.pain.2004.06.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66814881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304395904002957</els_id><sourcerecordid>66814881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-32ffc9e2393a1a4565703af452945331bb70a00e8bc6dc156aeb73c120ad69a43</originalsourceid><addsrcrecordid>eNp9kT2P1DAQhi0E4paDP0CB3EB1CWM7cRJEAye-pJNooLYmzvjWS2IvdhZEwX8nuY10HYXlDz3zavwMY88FlAKEfn0oj-hDKQGqEnQJon7AdqJtZKG1VA_ZDhRUherq7oI9yfkAAFLK7jG7ELWSTSvFjv19HwNxi8FS4mvcGz7viZNzZOfMo7u79j4f93FdAWfiOFIY0vkcw13ZFc8_aKQZR55oigONPtxe8fk0xcRvU_w97zmGYXsIZFPMPj9ljxyOmZ5t-yX7_vHDt-vPxc3XT1-u390UtmrUXCjpnO1Iqk6hwKrWdQMKXVXLrqqVEn3fAAJQ21s9WFFrpL5RVkjAQXdYqUv26px7TPHnifJsJp8tjSMGiqdstG5F1bZiAeUZXPvLiZw5Jj9h-mMEmFW6OZj1u2aVbkCbRfpS9GJLP_UTDfclm-UFeLkBmC2OLi26fb7nNLRKdmrh3p45Wlz88pRMtp6W0Qw-LeMwQ_T_6-Mf_XahbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66814881</pqid></control><display><type>article</type><title>Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Sevcik, Molly A. ; Luger, Nancy M. ; Mach, David B. ; Sabino, Mary Ann C. ; Peters, Christopher M. ; Ghilardi, Joseph R. ; Schwei, Matthew J. ; Röhrich, Heidi ; De Felipe, Carmen ; Kuskowski, Michael A. ; Mantyh, Patrick W.</creator><creatorcontrib>Sevcik, Molly A. ; Luger, Nancy M. ; Mach, David B. ; Sabino, Mary Ann C. ; Peters, Christopher M. ; Ghilardi, Joseph R. ; Schwei, Matthew J. ; Röhrich, Heidi ; De Felipe, Carmen ; Kuskowski, Michael A. ; Mantyh, Patrick W.</creatorcontrib><description>Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival.</description><identifier>ISSN: 0304-3959</identifier><identifier>EISSN: 1872-6623</identifier><identifier>DOI: 10.1016/j.pain.2004.06.015</identifier><identifier>PMID: 15327821</identifier><identifier>CODEN: PAINDB</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Activating Transcription Factor 3 ; Alendronate - pharmacology ; Animals ; Behavior, Animal ; Biological and medical sciences ; Biomarkers, Tumor ; Bone Neoplasms - complications ; Bone Neoplasms - drug therapy ; Bone Neoplasms - pathology ; Diseases of the osteoarticular system ; Male ; Medical sciences ; Mice ; Mice, Inbred C3H ; Mouse ; Necrosis ; Nociception ; Osteoclasts - drug effects ; Osteoclasts - pathology ; Osteolysis ; Osteolysis - drug therapy ; Osteolysis - etiology ; Osteolysis - pathology ; Pain - drug therapy ; Pain - etiology ; Pain - pathology ; Sarcoma ; Sarcoma - complications ; Sarcoma - drug therapy ; Sarcoma - pathology ; Transcription Factors - metabolism ; Tumors of striated muscle and skeleton</subject><ispartof>Pain (Amsterdam), 2004-09, Vol.111 (1), p.169-180</ispartof><rights>2004 International Association for the Study of Pain</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-32ffc9e2393a1a4565703af452945331bb70a00e8bc6dc156aeb73c120ad69a43</citedby><cites>FETCH-LOGICAL-c473t-32ffc9e2393a1a4565703af452945331bb70a00e8bc6dc156aeb73c120ad69a43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16083293$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15327821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sevcik, Molly A.</creatorcontrib><creatorcontrib>Luger, Nancy M.</creatorcontrib><creatorcontrib>Mach, David B.</creatorcontrib><creatorcontrib>Sabino, Mary Ann C.</creatorcontrib><creatorcontrib>Peters, Christopher M.</creatorcontrib><creatorcontrib>Ghilardi, Joseph R.</creatorcontrib><creatorcontrib>Schwei, Matthew J.</creatorcontrib><creatorcontrib>Röhrich, Heidi</creatorcontrib><creatorcontrib>De Felipe, Carmen</creatorcontrib><creatorcontrib>Kuskowski, Michael A.</creatorcontrib><creatorcontrib>Mantyh, Patrick W.</creatorcontrib><title>Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis</title><title>Pain (Amsterdam)</title><addtitle>Pain</addtitle><description>Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival.</description><subject>Activating Transcription Factor 3</subject><subject>Alendronate - pharmacology</subject><subject>Animals</subject><subject>Behavior, Animal</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor</subject><subject>Bone Neoplasms - complications</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - pathology</subject><subject>Diseases of the osteoarticular system</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Mouse</subject><subject>Necrosis</subject><subject>Nociception</subject><subject>Osteoclasts - drug effects</subject><subject>Osteoclasts - pathology</subject><subject>Osteolysis</subject><subject>Osteolysis - drug therapy</subject><subject>Osteolysis - etiology</subject><subject>Osteolysis - pathology</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><subject>Pain - pathology</subject><subject>Sarcoma</subject><subject>Sarcoma - complications</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - pathology</subject><subject>Transcription Factors - metabolism</subject><subject>Tumors of striated muscle and skeleton</subject><issn>0304-3959</issn><issn>1872-6623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kT2P1DAQhi0E4paDP0CB3EB1CWM7cRJEAye-pJNooLYmzvjWS2IvdhZEwX8nuY10HYXlDz3zavwMY88FlAKEfn0oj-hDKQGqEnQJon7AdqJtZKG1VA_ZDhRUherq7oI9yfkAAFLK7jG7ELWSTSvFjv19HwNxi8FS4mvcGz7viZNzZOfMo7u79j4f93FdAWfiOFIY0vkcw13ZFc8_aKQZR55oigONPtxe8fk0xcRvU_w97zmGYXsIZFPMPj9ljxyOmZ5t-yX7_vHDt-vPxc3XT1-u390UtmrUXCjpnO1Iqk6hwKrWdQMKXVXLrqqVEn3fAAJQ21s9WFFrpL5RVkjAQXdYqUv26px7TPHnifJsJp8tjSMGiqdstG5F1bZiAeUZXPvLiZw5Jj9h-mMEmFW6OZj1u2aVbkCbRfpS9GJLP_UTDfclm-UFeLkBmC2OLi26fb7nNLRKdmrh3p45Wlz88pRMtp6W0Qw-LeMwQ_T_6-Mf_XahbA</recordid><startdate>20040901</startdate><enddate>20040901</enddate><creator>Sevcik, Molly A.</creator><creator>Luger, Nancy M.</creator><creator>Mach, David B.</creator><creator>Sabino, Mary Ann C.</creator><creator>Peters, Christopher M.</creator><creator>Ghilardi, Joseph R.</creator><creator>Schwei, Matthew J.</creator><creator>Röhrich, Heidi</creator><creator>De Felipe, Carmen</creator><creator>Kuskowski, Michael A.</creator><creator>Mantyh, Patrick W.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040901</creationdate><title>Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis</title><author>Sevcik, Molly A. ; Luger, Nancy M. ; Mach, David B. ; Sabino, Mary Ann C. ; Peters, Christopher M. ; Ghilardi, Joseph R. ; Schwei, Matthew J. ; Röhrich, Heidi ; De Felipe, Carmen ; Kuskowski, Michael A. ; Mantyh, Patrick W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-32ffc9e2393a1a4565703af452945331bb70a00e8bc6dc156aeb73c120ad69a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Activating Transcription Factor 3</topic><topic>Alendronate - pharmacology</topic><topic>Animals</topic><topic>Behavior, Animal</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor</topic><topic>Bone Neoplasms - complications</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - pathology</topic><topic>Diseases of the osteoarticular system</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Mouse</topic><topic>Necrosis</topic><topic>Nociception</topic><topic>Osteoclasts - drug effects</topic><topic>Osteoclasts - pathology</topic><topic>Osteolysis</topic><topic>Osteolysis - drug therapy</topic><topic>Osteolysis - etiology</topic><topic>Osteolysis - pathology</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><topic>Pain - pathology</topic><topic>Sarcoma</topic><topic>Sarcoma - complications</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - pathology</topic><topic>Transcription Factors - metabolism</topic><topic>Tumors of striated muscle and skeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sevcik, Molly A.</creatorcontrib><creatorcontrib>Luger, Nancy M.</creatorcontrib><creatorcontrib>Mach, David B.</creatorcontrib><creatorcontrib>Sabino, Mary Ann C.</creatorcontrib><creatorcontrib>Peters, Christopher M.</creatorcontrib><creatorcontrib>Ghilardi, Joseph R.</creatorcontrib><creatorcontrib>Schwei, Matthew J.</creatorcontrib><creatorcontrib>Röhrich, Heidi</creatorcontrib><creatorcontrib>De Felipe, Carmen</creatorcontrib><creatorcontrib>Kuskowski, Michael A.</creatorcontrib><creatorcontrib>Mantyh, Patrick W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pain (Amsterdam)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sevcik, Molly A.</au><au>Luger, Nancy M.</au><au>Mach, David B.</au><au>Sabino, Mary Ann C.</au><au>Peters, Christopher M.</au><au>Ghilardi, Joseph R.</au><au>Schwei, Matthew J.</au><au>Röhrich, Heidi</au><au>De Felipe, Carmen</au><au>Kuskowski, Michael A.</au><au>Mantyh, Patrick W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis</atitle><jtitle>Pain (Amsterdam)</jtitle><addtitle>Pain</addtitle><date>2004-09-01</date><risdate>2004</risdate><volume>111</volume><issue>1</issue><spage>169</spage><epage>180</epage><pages>169-180</pages><issn>0304-3959</issn><eissn>1872-6623</eissn><coden>PAINDB</coden><abstract>Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15327821</pmid><doi>10.1016/j.pain.2004.06.015</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3959 |
| ispartof | Pain (Amsterdam), 2004-09, Vol.111 (1), p.169-180 |
| issn | 0304-3959 1872-6623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66814881 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Activating Transcription Factor 3 Alendronate - pharmacology Animals Behavior, Animal Biological and medical sciences Biomarkers, Tumor Bone Neoplasms - complications Bone Neoplasms - drug therapy Bone Neoplasms - pathology Diseases of the osteoarticular system Male Medical sciences Mice Mice, Inbred C3H Mouse Necrosis Nociception Osteoclasts - drug effects Osteoclasts - pathology Osteolysis Osteolysis - drug therapy Osteolysis - etiology Osteolysis - pathology Pain - drug therapy Pain - etiology Pain - pathology Sarcoma Sarcoma - complications Sarcoma - drug therapy Sarcoma - pathology Transcription Factors - metabolism Tumors of striated muscle and skeleton |
| title | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A51%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20cancer%20pain:%20the%20effects%20of%20the%20bisphosphonate%20alendronate%20on%20pain,%20skeletal%20remodeling,%20tumor%20growth%20and%20tumor%20necrosis&rft.jtitle=Pain%20(Amsterdam)&rft.au=Sevcik,%20Molly%20A.&rft.date=2004-09-01&rft.volume=111&rft.issue=1&rft.spage=169&rft.epage=180&rft.pages=169-180&rft.issn=0304-3959&rft.eissn=1872-6623&rft.coden=PAINDB&rft_id=info:doi/10.1016/j.pain.2004.06.015&rft_dat=%3Cproquest_cross%3E66814881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66814881&rft_id=info:pmid/15327821&rft_els_id=S0304395904002957&rfr_iscdi=true |